Automated surface-bound oligoseed DNA amplification enabling advanced therapies and diagnostics

合成DNA是广泛的成熟和新兴行业的主流组成部分，包括细胞和基因治疗以及分子诊断。到2025年，全球DNA合成市场预计将达到34亿英镑，未来几年需求将达到数百公斤，远远超过供应。固相磷酸酰胺化学是过去40年来主要的DNA生产方法，但存在过度依赖危险化学品、准确性和长度有限、制造延迟、运输成本高、产量/质量低等问题。高DNA产量在很大程度上依赖于通过质粒克隆到细菌中的制造水平的扩大，这带来了安全问题，并且是一个昂贵的制造瓶颈。英国政府生命科学战略优先考虑提高分子疗法和先进诊断方法的开发和生产，并建立抵御未来流行病的能力。这将依赖于多功能、低成本、高产率寡核苷酸合成的新工具。在该项目中，nunibio将应用他们的多项专利技术来打造一种新的改进的DNA合成方法，这将减少制造和运输延迟，增加工作流程的自主性和控制，减少溶剂的使用和污染，并以更快、更低的成本生产更多的即用材料。该项目的产出将有助于节省5.83亿英镑的未来工业成本，并在2029年之前从工业用途中去除440万升有害的酰胺磷合成试剂。

Synthetic DNA is a mainstream component for wide-ranging established and emerging industries including cell and gene therapies and molecular diagnostics. The global DNA synthesis market is forecast to reach £3.4bn by 2025, with demand reaching hundreds of kilograms in coming years and vastly outstripping supply. Solid phase phosphoramidite chemistry, the mainstay DNA production method over the past 40 years, suffers from over-dependence on hazardous chemicals, limited accuracy and length, manufacturing delays, expensive shipping, and low yield/quality. High DNA yields largely rely on manufacturing-level scale-up by cloning via plasmid into bacteria, which poses safety concerns and is a costly manufacturing bottleneck. The UK Government Life Sciences Strategy prioritises an escalation in molecular therapeutics and advanced diagnostics development and manufacture, and to build resilience against future pandemics. This will depend on new tools for versatile, low-cost, high yield oligonucleotide synthesis. In the project, Nunabio will apply their multi-patented technology to forge a new improved means of DNA synthesis that will reduce manufacture and shipping delays, increase workflow autonomy and control, reduce solvent usage and contamination, and produce more ready-to-use material, faster and at lower cost. The outputs of the project will help save £583Mn in future industry costs and remove 4.4Mn litres of harmful phosphoramidite synthesis reagents from industrial use by 2029\.